Tekmira's Partner Announces Positive Clinical Data For LNP-Enabled Patisiran

(RTTNews) - Tekmira Pharmaceuticals Corp. (TKMR) (TKM.TO) Tuesday reported that its partner Alnylam Pharmaceuticals, Inc. (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension or OLE study in patients with Familial Amyloidotic Polyneuropathy or FAP.

Patisiran (ALN-TTR02) is an RNAi therapeutic targeting transthyretin or TTR in development for the treatment of TTR-mediated amyloidosis, which is enabled by Tekmira's lipid nanoparticle or LNP technology.

Alnylam presented data at the American Neurological Association's 2014 Annual Meeting held October 12 - 14 in Baltimore. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score or mNIS+7 at six months in 19 patients with mNIS+7 data available for the current analysis.

Dr. Mark Murray, Tekmira's President and CEO, said, "We are pleased with the positive results reported today in Alnylam's patisiran development program, demonstrating sustained knockdown of serum TTR of up to 90% and a favorable tolerability profile out to one year of treatment."

He said this program is enabled by Tekmira's LNP technology and represents the most clinically advanced application of Tekmira's proprietary LNP delivery technology.